JP7862320B2 - 遺伝子治療の増強のためのアデノ随伴ウイルス(aav)の制御された修飾 - Google Patents

遺伝子治療の増強のためのアデノ随伴ウイルス(aav)の制御された修飾

Info

Publication number
JP7862320B2
JP7862320B2 JP2022563990A JP2022563990A JP7862320B2 JP 7862320 B2 JP7862320 B2 JP 7862320B2 JP 2022563990 A JP2022563990 A JP 2022563990A JP 2022563990 A JP2022563990 A JP 2022563990A JP 7862320 B2 JP7862320 B2 JP 7862320B2
Authority
JP
Japan
Prior art keywords
aav
amino acid
capsid
capsid protein
genetically modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022563990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524401A5 (cg-RX-API-DMAC7.html
JP2023524401A (ja
Inventor
アビシェク チャッテルジー
レイチェル イー. ケレメン
サラ ビー. エリックソン
チュアン ファム
Original Assignee
トラスティーズ オブ ボストン カレッジ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トラスティーズ オブ ボストン カレッジ filed Critical トラスティーズ オブ ボストン カレッジ
Publication of JP2023524401A publication Critical patent/JP2023524401A/ja
Publication of JP2023524401A5 publication Critical patent/JP2023524401A5/ja
Priority to JP2025267976A priority Critical patent/JP2026062759A/ja
Application granted granted Critical
Publication of JP7862320B2 publication Critical patent/JP7862320B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022563990A 2020-05-01 2021-05-03 遺伝子治療の増強のためのアデノ随伴ウイルス(aav)の制御された修飾 Active JP7862320B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025267976A JP2026062759A (ja) 2020-05-01 2025-12-19 遺伝子治療の増強のためのアデノ随伴ウイルス(aav)の制御された修飾

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063018573P 2020-05-01 2020-05-01
US63/018,573 2020-05-01
PCT/US2021/030489 WO2021222899A1 (en) 2020-05-01 2021-05-03 Controlled modification of adeno-associated virus (aav) for enhanced gene therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025267976A Division JP2026062759A (ja) 2020-05-01 2025-12-19 遺伝子治療の増強のためのアデノ随伴ウイルス(aav)の制御された修飾

Publications (3)

Publication Number Publication Date
JP2023524401A JP2023524401A (ja) 2023-06-12
JP2023524401A5 JP2023524401A5 (cg-RX-API-DMAC7.html) 2024-05-08
JP7862320B2 true JP7862320B2 (ja) 2026-05-19

Family

ID=76392408

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022563990A Active JP7862320B2 (ja) 2020-05-01 2021-05-03 遺伝子治療の増強のためのアデノ随伴ウイルス(aav)の制御された修飾
JP2025267976A Pending JP2026062759A (ja) 2020-05-01 2025-12-19 遺伝子治療の増強のためのアデノ随伴ウイルス(aav)の制御された修飾

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025267976A Pending JP2026062759A (ja) 2020-05-01 2025-12-19 遺伝子治療の増強のためのアデノ随伴ウイルス(aav)の制御された修飾

Country Status (9)

Country Link
US (1) US20230175013A1 (cg-RX-API-DMAC7.html)
EP (1) EP4143206A1 (cg-RX-API-DMAC7.html)
JP (2) JP7862320B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230005941A (cg-RX-API-DMAC7.html)
CN (1) CN115551878A (cg-RX-API-DMAC7.html)
AU (1) AU2021264081A1 (cg-RX-API-DMAC7.html)
CA (1) CA3177573A1 (cg-RX-API-DMAC7.html)
IL (1) IL297780A (cg-RX-API-DMAC7.html)
WO (1) WO2021222899A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116333058A (zh) * 2023-02-14 2023-06-27 国家纳米科学中心 可定点修饰抗原的病毒样颗粒及其构建方法与应用
WO2025188967A1 (en) 2024-03-06 2025-09-12 Trustees Of Boston College Precise adeno-associated virus-protein conjugates and uses thereof
TW202609054A (zh) * 2024-05-01 2026-03-01 日商Jcr製藥股份有限公司 經修飾之aav粒子、其製造方法、相關之醫藥及其製造方法
WO2026037731A1 (en) 2024-08-12 2026-02-19 Coave Therapeutics Squaramide-modified viral vectors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160297855A1 (en) 2013-10-30 2016-10-13 Peking University Adeno-Associated Virus with Site-Directed Mutagenesis and Site-Directed Modification and Preparation Method and Application Thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4480268B2 (ja) * 1998-02-12 2010-06-16 イミューン コンプレックス コーポレイション 戦略的修飾されたb型肝炎コアタンパク質及びそれらの誘導体
PL2657248T3 (pl) * 2003-06-19 2017-09-29 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
EP1828390B1 (en) * 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
EP2396343B1 (en) * 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
JP6836999B2 (ja) * 2015-03-24 2021-03-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California アデノ随伴ウイルス変異体及びその使用方法
WO2019221992A1 (en) * 2018-05-15 2019-11-21 President And Fellows Of Harvard College Viral vectors exhibiting improved gene delivery properties

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160297855A1 (en) 2013-10-30 2016-10-13 Peking University Adeno-Associated Virus with Site-Directed Mutagenesis and Site-Directed Modification and Preparation Method and Application Thereof

Also Published As

Publication number Publication date
WO2021222899A1 (en) 2021-11-04
JP2026062759A (ja) 2026-04-10
EP4143206A1 (en) 2023-03-08
JP2023524401A (ja) 2023-06-12
US20230175013A1 (en) 2023-06-08
IL297780A (en) 2022-12-01
CN115551878A (zh) 2022-12-30
CA3177573A1 (en) 2021-11-04
KR20230005941A (ko) 2023-01-10
AU2021264081A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
JP2026062759A (ja) 遺伝子治療の増強のためのアデノ随伴ウイルス(aav)の制御された修飾
CN112041451B (zh) 基于aav的基因和蛋白质递送模块化系统
US10087217B2 (en) Adeno-associated virus with site-directed mutagenesis and site-directed modification and preparation method and application thereof
KR20200130337A (ko) Aav 키메라
CN112566923A (zh) 合成嗜肝性腺相关病毒衣壳及其用途
KR20200033840A (ko) 개선된 세포 트랜스펙션 및/또는 rAAV 벡터 생산을 위한 증진제
WO2002053703A2 (en) Aav2 vectors and methods
US20250325696A1 (en) Mutant of adeno-associated virus and use thereof
JP2023524401A5 (cg-RX-API-DMAC7.html)
JP7811576B2 (ja) SARS-CoV-2に対するAAV5に基づくワクチン
CN119095973A (zh) 腺相关病毒的缀合
US12037597B2 (en) Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells
CA3092451C (en) A modular system for gene and protein delivery based on aav
Wang Role of the AAV receptor in AAV cell entry and trafficking
WO2024249438A1 (en) Copiparvovirus genetic vector platform
WO2025188967A1 (en) Precise adeno-associated virus-protein conjugates and uses thereof
AU2024301586A1 (en) Methods of preparing surface modified viral capsids
Fu Production of VP3-Only AAV2 VLP in E. coli
Le Analysis, Optimization and Application of AAV Capsid Assembly using Escherichia coli
WO2025241027A1 (en) Vectors encapsidating nucleic acids, production methods and uses thereof
JP3095248B2 (ja) 核酸運搬体
Kelemen et al. Incorporation of unnatural amino acids into the capsid of adeno-associated virus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250612

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260316

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260507

R150 Certificate of patent or registration of utility model

Ref document number: 7862320

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150